Table 5.
Cox regression analysis with regard to the CTLA-4 haplotype H1: TAA.
| Variable | 90 Days | |||||
| Univariate Analysis | Multivariate Analysis | |||||
| Hazard Ratio | 95% CI | p-Value | Hazard Ratio | 95% CI | p-Value | |
| Age | 1.032 | 1.020–1.043 | 0.000000 | 1.025 | 1.013–1.038 | 0.000049 |
| Male gender | 1.093 | 0.810–1.474 | 0.558922 | 1.079 | 0.798–1.459 | 0.620112 |
| BMI | 0.985 | 0.961–1.009 | 0.218173 | 0.975 | 0.950–1.001 | 0.061158 |
| SOFA score day 1 | 1.104 | 1.065–1.143 | 0.000000 | 1.038 | 0.988–1.091 | 0.139057 |
| APACHE II score day 1 | 1.069 | 1.046–1.092 | 0.000000 | 1.027 | 0.997–1.057 | 0.078734 |
| Statin therapy | 1.114 | 0.807–1.536 | 0.511644 | 1.086 | 0.777–1.519 | 0.629022 |
| Renal replacement therapy during observation period | 2.854 | 2.134–3.817 | 0.000000 | 2.724 | 1.867–3.974 | 0.000000 |
| Renal replacement therapy upon sepsis onset | 1.565 | 1.021–2.399 | 0.040064 | 1.973 | 1.192–3.268 | 0.008241 |
| H1: TAA negative | 0.698 | 0.504–0.967 | 0.030812 | 0.685 | 0.491–0.956 | 0.026202 |
| 28 Days | ||||||
| Univariate Analysis | Multivariate Analysis | |||||
| Age | 1.029 | 1.015–1.043 | 0.000035 | 1.023 | 1.009–1.039 | 0.001984 |
| Male gender | 1.278 | 0.875–1.866 | 0.204154 | 1.269 | 0.866–1.859 | 0.221286 |
| BMI | 0.982 | 0.953–1.013 | 0.252686 | 0.972 | 0.940–1.004 | 0.089311 |
| SOFA score day 1 | 1.119 | 1.071–1.169 | 0.000000 | 1.050 | 0.988–1.116 | 0.118403 |
| APACHE II score day 1 | 1.073 | 1.045–1.102 | 0.000000 | 1.026 | 0.990–1.064 | 0.155294 |
| Statin therapy | 0.964 | 0.641–1.451 | 0.861906 | 0.790 | 0.517–1.209 | 0.278234 |
| Renal replacement therapy during observation period | 3.028 | 2.131–4.301 | 0.000000 | 2.772 | 1.769–4.343 | 0.000009 |
| Renal replacement therapy upon sepsis onset | 1.616 | 0.970–2.691 | 0.065366 | 1.933 | 1.060–3.524 | 0.031464 |
| H1: TAA negative | 0.632 | 0.418–0.955 | 0.029340 | 0.621 | 0.407–0.947 | 0.027008 |